at 20/12/2024
Financial Documents & Rendez-Vous
Dear shareholders,
Welcome to your dedicated space, where you can find all the latest information about DMS Group quoted on the Euronext Growth Paris market (ISIN: FR0012202497 - mnemo: ALDMS).
READ THE LATEST INVESTOR PRESENTATION:
– [EN] PDF | DMS Group Overview
– [FR] PDF | Présentation Résultats 2024 et CA T1 2025
DISCOVER THE LATEST FINANCIAL ANALYSIS:
– EuroLand Coporate : Growth in line with expectations in Q1, ahead of H2 acceleration
IMAGING 2027
Imaging 2027 is DMS Group's strategic plan to establish the company as a key medical imaging player in Europe.
As part of this plan, DMS Group has set ambitious targets for 2027:
Accelerate growth and achieve a revenue of at least €70M
Improve profitability and aim for an EBITDA margin of 14%
FINANCIAL APPOINTMENTS
DATE
DOCUMENT
21 July 2025
Revenue for the 1st half of 2025
29 September 2025
Half-year results 2025
20 October 2025
Revenue for the 3rd quarter of 2025
19 January 2026
Revenue for 2025
CAPITAL ALLOCATION
CEO
Samuel SANCERNI
+33 4 66 29 09 07
INVESTOR RELATIONS
PRESS RELATIONS
For information about European Medical Solutions (formerly DMS Imaging), click here.